CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats. Australia-headquartered CSL remained scant on details, though it said the planned investment will “generate hundreds of high-quality American jobs”. The US expansion will strengthen the company’s plasma-derived therapies (PDTs) manufacturing, along with securing the company’s supply chain in the country. CSL said the ca ...